期刊文献+

不同剂量阿折地平在中国健康人体内的药代动力学 被引量:1

Pharmacokinetics of different dosages of azelnidipine in healthy volunteers
原文传递
导出
摘要 目的研究阿折地平(抗高血压药)在健康人体的药代动力学。方法 24名健康受试者分为3组,单次口服高、低(16,8 mg)2个剂量组和多次口服剂量组(每天服药1次,每次8 mg,连续服药7 d)。用液相串联质谱法测定血浆中阿折地平的血药浓度变化,药代动力学参数以SPSS 13.0软件求算。结果阿折地平高、低剂量组及多次给药组的代谢参数如下:Cmax分别为(10.61±3.93),(5.91±2.83)和(5.88±1.90)μg.L-1;Tmax分别为(3.67±0.99),(3.33±1.30)和(3.17±0.72)h;t1/2分别为(28.00±7.72),(20.34±7.60)和(28.17±7.93)h;AUC0-t分别为(139.50±72.90),(61.17±33.78)和(86.72±41.59)μg.h.L-1。多次给药的稳态AUCss(55.54±18.78)μg.h.L-1。健康受试者口服阿折地平片8,16 mg后,主要药代动力学参数除t1/2外,AUC0-t/D、AUC0-∞/D、Cmax/D在2个剂量组间均无统计学差异。多次给药t1/2与单次给药t1/2相比有所升高,CLz/F略有下降,具有统计学意义(P<0.05)。结论阿折地平在中国健康人体内在8~16 mg内呈线性药代动力学特征;本品每天给药1次,在中国人体内几无蓄积作用。 Objective To study the pharmacokinetics of different dosages of azelnidipine in Chinese healthy volunteers.Methods Twenty-four healthy volunteers were devided into three groups.The volunteers in the three groups received single dose of 16 mg azelnidipine,single dose of 8 mg azelnidipine and multiple dosing of 8 mg azelnidipine by oral administration(8 mg per day,7 days continuous),respectively.Concentrations of azelnidipine in plasma were determined by HPLC/MS/MS.The pharmacokinetics parameters were calculated by SPSS 13.0 software.Results The main pharmacokinetic parameters of the three groups were as follows: Cmax were(10.61±3.93),(5.91±2.83) and(5.88±1.90) μg·L-1;Tmax were(3.67±0.99),(3.33±1.30) and(3.17±0.72) h;t1/2 were(28.00±7.72),(20.34±7.60) and(28.17±7.93)h;AUC0-t were(139.50±72.90),(61.17±33.78)and(86.72±41.59) μg·h·L-1.respectively.The steady-state AUCss for multiple was(55.54±18.78) μg·h·L-1.The main pharmacokinetics parameters had no significant difference in AUC0-t /D,AUC0-∞/D,Cmax/D except t1/2.The half-time of multiple dosing was longer than that of single dose and there was a decline in the values of CLz/F,which had statistical difference(P0.05).Conclusion Pharmacokinetic characteristics of azelnidipine in Chinese healthy volunteers showed a linear relationship,within the dose range of 8-16 mg;Azelnidipine with administration of a single oral dose daily had almost no accumulation effect in Chinese.
出处 《中国临床药理学杂志》 CAS CSCD 北大核心 2012年第3期175-178,共4页 The Chinese Journal of Clinical Pharmacology
关键词 阿折地平 药代动力学 液相串联质谱法 azelnidipine pharmacokinetics HPLC/MS/MS
  • 相关文献

参考文献4

  • 1陈爱华,邬蓉,陶霞.阿折地平:一种新型二氢吡啶类钙拮抗药[J].中国新药与临床杂志,2006,25(12):946-949. 被引量:9
  • 2国家食品药品监督管理局药审中心.化学药物临床药代动力学研究技术指导原则[EB/OL].http:www//cde.org.cn,2010-09-06.
  • 3Kiyoshi K,Yoko U.Simultaneous determination of azelnidipine andtwo metabolites in human plasma using liquid chromatography-tan-dem mass spectrometry[J].J Chromatogr B,2006;844:45-52.
  • 4Ding L,Li L,Ma PC.Determination of azelnidipine in human plas-ma by liquid chromatography-electrospray ionization-mass spec-trometry[J].J Pharm Biomed Anal,2007;43:575-579.

二级参考文献14

  • 1WELLINGTON K,SCOTT LJ.Azelnidipine[J].Drugs,2003,63(23):2613-2621.
  • 2OIZUMI K,NISHINO H,MIYAKE S,et al.Hemodynamic changes following long-term administration of CS-905,a novel dihydropyridine calcium blocker,in conscious SHR[J].Jpn J Pharmacol,1990,54(1):1-6.
  • 3OIZUMI K,MIYAMOTO M,KOIKE H.Antihypertensive effect of CS-905,a novel dihydropyridine calcium blocker,in conscious hypertensive dogs[J].Jpn J Pharmacol,1990,53(2):264-266.
  • 4ARITA M,HASHIZUME T,TANIGAWA K,et al.A new caantagonist,azelnidipine,reduced blood pressure during exercise without augmentation of sympathetic nervous system in essential hypertension:a randomized,double-blind,placebocontrolled trial[J].J Cardiovasc Pharmacol,1999,33(2):186-192.
  • 5SADA T,SAITO H.Pharmacological profiles and clinical effects of azelnidipine,a long-acting calcium channel blocker[J].Nippon Yakurigaku Zasshi,2003,122(6):539-547.
  • 6KURAMOTO K,ICHIKAWA S,HIRAI A,et al.Azelnidipine and amlodipine:a comparison of their pharmacokinetics and effects on ambulatory blood pressure[J].Hypertens Res,2003,26(3):201-208.
  • 7OIZUMI K,MIYAMOTO M,KOIKE H.Beneficial renal effects of CS-905,a novel dihydropyridine calcium blocker in SHR[J].Jpn J Pharmacol,1989,51 (4):501-508.
  • 8KANAZAWA M,KOHZUKI M,YOSHDA K,et al.Combination therapy with an angiotensin-converting enzyme (ACE)inhibitor and a calcium antagonist:beyond the renoprotective effects of ACE inhibitor monotherapy in a spontaneous hypertensive rat with renal ablation[J].Hypertens Res,2002,25(3):447-453.
  • 9SATOH K,YAMAMOTO A,HOSHI K,et al.Effects of azelnidipine,a dihydropyridine calcium antagonist,on myocardial stunning in dogs[J].Jpn J Pharmacol,1998,76(4):369-376.
  • 10NAKASHIMA M,KAWABATA K,SASAHARA K.Phase Ⅰstudy of CS-905,a new calcium antagonist-Ⅱ:a single dose study on healthy vounteers:influence of food intake[J].Rinsho Iyaku,2000,16 (2):179.

共引文献9

同被引文献14

  • 1Wellington K,Scott LJ. Azelnidipine[J].{H}DRUGS,2003,(23):2613-2621.
  • 2Mitsuyoshi K,Kiyoshi K,Kunihiro S. Phase I Study of CS-905, a New Calcium Antagonist. II. A Single Dose Study on Healthy Volunteers:Influence of Food Intake[J].Rinsho lyaku,2000,(02):179.
  • 3Jinno T,Iwai M,Li Z. Calcium Channel blocker azelnidipine enhances vascular protective effects of AT1 receptor blocker olmesartan[J].{H}HYPERTENSION,2004,(02):263-269.
  • 4ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group,The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Major outcomes in moderately hypercholesterolemic,hypertensive patients randomized to pravastatin vs usual care:The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial(ALLHAT-LLT)[J].{H}JAMA:the Journal of the American Medical Association,2002,(23):2998-3007.
  • 5Julius S,Kjeldsen SE,Weber M. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine:the VALUE randomised trial[J].{H}LANCET,2004,(9426):2022-2031.
  • 6Dahl?f B,Sever PS,Poulter NR. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required,in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm(ASCOT-BPLA):a multicentre randomised controlled trial[J].{H}LANCET,2005,(9489):895-906.
  • 7Arita M,Hashizume T,Tanigawa K. A new Ca-antagonist,azelnidipine,reduced blood pressure during exercise without augmentation of sympathetic nervous system in essential hypertension:a randomized,double-blind,placebo-controlled trial[J].{H}Journal of Cardiovascular Pharmacology,1999,(02):186-192.
  • 8Yoshinaga K,Iimura O,Abe K. Late phase II study of CS-905,azelnidipine,in patients with essential hypertension:a multi-center,double-blind comparative study for evaluation of optimal dose[J].Rinsho Iyaku,1999,(06):907.
  • 9Kuramoto K,Ichikawa S,Hirai A. Azelnidipine and amlodipine:a comparison of their pharmacokinetics and effects on ambulatory blood pressure[J].{H}Hypertension Research,2003,(03):201-208.
  • 10Yoshinaga K,Iimur O,Abe K. A multicenter doubleblind comparison study of CS-905(azelnidipine)with nitrendipine in patients with essential hypertension[J].Rinsho lyaku,2000,(05):671.

引证文献1

二级引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部